★★

Plasmapp

Plasmapp's 1Q26 Operating Loss Continues, Financial Burden Rises, New Product Launch Imminent


  • Consolidated revenue in 1Q26 reached KRW 2.82 billion (171% increase YoY from KRW 1.04 billion), but operating loss was KRW 2.15 billion (vs. KRW 1.70 billion loss in prior year), continuing losses
  • Net loss of KRW 2.32 billion (vs. KRW 2.66 billion loss in prior year), basic EPS loss of KRW 604
  • At end of quarter, total borrowings: KRW 9.78 billion, cash: KRW 2.18 billion, net debt: KRW 7.60 billion, debt-to-equity ratio: 218.4% (soared from 92.6% at year-end)
  • For 2nd convertible bond (balance KRW 10 billion): call and put options waived, yield to maturity changed to 0%; major shareholder Dreamtech provides joint guarantee
  • Derivative liability (conversion right) valued at KRW 2.17 billion (fair value), underlying asset price KRW 5,800, volatility 3.14%
  • R&D expenses: KRW 740 million (26.4% of revenue); new products Plasma Steri 700 and PLASMA ENDO expected to launch in H2 2026
  • No dividends (none for past 3 years), no share buyback or cancellation
  • Subsidiary Plasmapp America Inc. recorded net profit of KRW 500 million

KOSDAQ Filing Information


  • Filing: Quarterly Report (2026.03)
  • Company: Plasmapp (405000)
  • Submission: Plasmapp Co., Ltd.
  • Receipt: 05-15-2026